'김갑성' 기자의 전체기사
-
New Public Perception Survey Highlights Fragmented Cancer…
YouGov survey finds strong belief in value of early detection (79%) but low screening uptake (25%) 82% of respondents aware post-treatment care exists, 55% lack understanding of what it involves Findings show confidence in "one-stop" cancer services and openness to digital innovation KUALA LUMPUR, Malaysia, Sept. 10, 2025 -- Public perceptions of cancer care in Malaysia show critical gaps across the pathway from screening and diagnosis through to treatment and survivorship, according to new research commissioned by Siemens Healthineers. B
- 김갑성 기자
- 2025-09-10 09:00
-
Allianz Partners appoints Okan Özdemir as its new Chief Offic…
PARIS, Sept. 10, 2025 -- Allianz Partners, a global leader in insurance and assistance services, is pleased to announce the appointment of Okan Özdemir as its new Chief Officer for Health and Board Member, effective September 1, 2025. In this role, Okan will report directly to Allianz Partners CEO Tomas Kunzmann. Okan Özdemir joins Allianz Partners from Allianz Türkiye, where he served as Chief Health Officer and Executive Board Member since 2019. With over 24 years of strong leadership at Allianz in a number of strategic roles including Chief Mark
- 김갑성 기자
- 2025-09-10 09:00
-
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imag…
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis. BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study[1]) is the first registration-enabling study to evaluate whether the combination of MRI[2] and PSMA-PET[3] imaging can impro
- 김갑성 기자
- 2025-09-10 07:01
-
TCI Biotech Strengthens Global Leadership Team with Appo…
SALT LAKE CITY, Utah, Sept. 9, 2025 -- TCI, a global biotechnology leader in health and wellness innovation, today announced key leadership appointments to accelerate its international growth. Tony Hatori has been named Vice President of Sales, while Alan Roberts joins as Strategic Consultant for the U.S. market. These appointments underscore TCI's commitment to advancing a science-driven, asset-light, and globally integrated enterprise. Asset-Light, Regionally Responsive Manufacturing & Science-Driven Innovation TCI Biotech has adopted an asset-light global manufacturing m
- 김갑성 기자
- 2025-09-09 23:00
-
CAS introduces CAS IP Finder for improved intellectual property…
The AI-enhanced solution deepens search capabilities and improves user experience COLUMBUS, Ohio, Sept. 9, 2025 -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces the introduction of CAS IP Finder, powered by STN™. This new intellectual property search solution expands on the trusted foundation of CAS STNext®, the premier scientific IP information platform for expert-level precision search across scientific and patent databases. CAS STNext supports intellectual property professionals with advanced capabilities, co
- 김갑성 기자
- 2025-09-09 21:01
-
CAS, 지식재산권 검색 개선을 위한 CAS IP Finder 출시
AI 강화 솔루션으로 검색 역량 강화 및 사용자 경험 개선 콜럼버스, 오하이오, 2025년 9월 9일 -- 미국화학회(American Chemical Society) 산하 과학 지식 관리 전문 기관인 CAS가 새로운 지식재산권 검색 솔루션인 CAS IP Finder (STN™ 제작)를 공개했다. 이 솔루션은 CAS의 대표적인 과학 지식재산(IP) 검색 플랫폼인 CAS STNext®의 신뢰성을 기반으로 개발됐으며, 과학 및 특허 데이터베이스 전반에 걸친 전문가 수준의 정밀 검색 기능을 한층 확장했다. CAS STNext는 전 세계 데이터베이스, 과학자 큐레이션 콘텐츠, 특허 정보를 포괄적으로 제공하며, 정밀 검색 및 분석 도구를 통해 지식재산권 전문가들을 지원한다. CAS IP Finder™는 AI 강화 기능과 확장된 콘텐츠를 도입해 더 넓은 사용자층이 정밀 검색에 더 쉽게 접근할 수 있도록 설계했다. 이 솔루션은 2025년 가을에 공식 출시되며, 추가 기능이 단계적으로 제공될 예정이다. 지식 재산권 분야에서 기업의 진화하는 지식재산 검색 니즈에 대응하기 위해 개발된 CAS IP Finder는 조직이 더 빠르게
- 김갑성 기자
- 2025-09-09 21:01
-
Metabolon Partners with China Kadoorie Biobank to Advance…
The landmark multiomics study will examine how lifestyle, environmental, socioeconomic, and genetic factors play a significant role in shaping common diseases MORRISVILLE, N.C., Sept. 9, 2025 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announced today it was chosen by the China Kadoorie Biobank (CKB) to profile plasma metabolomics biomarkers, using Metabolon's Global Discovery Panel™. CKB is one of the world's largest and mos
- 김갑성 기자
- 2025-09-09 21:00
-
iRegene Therapeutics Secures Series B+ Financing Follow…
CHENGDU, China, Sept. 9, 2025 -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Northern Light Venture Capital, Chuangjing Capital, and OneHealth Haihe Capital, along with participation from other investors. In August 2025, NouvNeu001 received Fast Track Designation (FTD) from the U.S. FDA, making it the world's first allogeneic iPSC-derived cell therapy for Parkinson's diseas
- 김갑성 기자
- 2025-09-09 21:00
-
XtalPi AI Drug Discovery Collaboration Reaches Milestone as…
SHENZHEN, China, Sept. 9, 2025 -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia's Human Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreemen
- 김갑성 기자
- 2025-09-09 20:42
-
RingConn Showcases Blood Pressure Insights Demo at IFA 2…
BERLIN, Sept. 9, 2025 -- RingConn, the leading smart ring brand, announced its participation in the 2025 IFA Berlin, where it unveiled a demo of its upcoming Blood Pressure Insights feature. This marks the first public showcase of the technology and a major step forward in RingConn's mission to empower people with comprehensive, science-driven health management tools. First Look at Blood Pressure InsightsAt the booth, RingConn presented a demo of the Blood Pressure Insights feature currently under development. Since the company's founding, the R&D team has been dedicated to
- 김갑성 기자
- 2025-09-09 19:15
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
2025-10-21_TUE
- AESOP Technology announces DxPrime is now a qualified solution on Mayo Clinic Platform 23:30
- Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq 23:00
- Stéphane Rolland's Haute Couture to Illuminate the 10th Anniversary of Barcelona Bridal Night 23:00
- JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène 22:00
- AI meets capital: Bizcap welcomes 8fig into its global portfolio to accelerate growth funding 22:00
- Youth Innovation Safeguards Green Heritage: 2025 World Food Forum Youth Action on Green Agri-Heritage Held in Rome 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 03시 00분